ARTHROPLASTY
Similar blood loss and lower cost with oral TXA vs. both IA TXA and IV TXA in total hip arthroplasty
J Arthroplasty. 2018 Mar;33(3):786-793180 patients scheduled for total hip arthroplasty were randomized to oral tranexamic acid, intravenous tranexamic acid, or intraarticular tranexamic acid. Results demonstrated no significant differences between the three groups in hemoglobin drop, total blood loss, or transfusion rate. Additionally, no patient in any of the groups developed DVT or PE. Cost analysis demonstrated significantly lower cost associated with oral tranexamic acid when compared to both IV tranexamic acid and IA tranexamic acid.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
